

Revision date: 28-Aug-2009 Version: 2.2 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Metronidazole 500 mg IV Infusion

Trade Name: Flagyl Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antiprotozoal agent

2. HAZARDS IDENTIFICATION

Appearance: Pale greenish/yellow sterile solution

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Ingestion of large amounts may cause central nervous system effects.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Suspected of

causing cancer.

Known Clinical Effects: Clinical use of this drug has caused peripheral neuropathy, associated with numbness and

tingling of the extremities, pain, and motor weakness. Effects on blood and blood-forming

organs have also occurred.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not

apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Metronidazole	443-48-1	207-136-1	Xn;R40-63	0.5
Citric Acid	77-92-9	201-069-1	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Sodium Phosphate	7632-05-5	231-558-5	Not Listed	*

Material Name: Metronidazole 500 mg IV Infusion Page 2 of 7 Version: 2.2

Revision date: 28-Aug-2009

SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention **Eye Contact:**

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

During all fire fighting activities, wear appropriate protective equipment, including self-Fire Fighting Procedures:

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Metronidazole 500 mg IV Infusion Page 3 of 7 Version: 2.2

Revision date: 28-Aug-2009

7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use

appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Metronidazole

Netherlands OEL - TWA Listed

SODIUM CHLORIDE

Listed **Latvia OEL - TWA** Lithuania OEL - TWA Listed

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Metronidazole

Pfizer Occupational Exposure OEB2 (control exposure to the range of >100ug/m³ to < 1000ug/m³)

Band (OEB):

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Refer to specific Member State legislation for requirements under Community environmental **Environmental Exposure Controls:**

legislation.

Refer to applicable national standards and regulations in the selection and use of personal **Personal Protective Equipment:**

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Wear safety glasses or goggles if eye contact is possible. Eyes:

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear Respiratory protection:

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Color: Solution Clear greenish/yellow

Molecular Formula: Mixture Mixture **Molecular Weight:**

Page 4 of 7

Material Name: Metronidazole 500 mg IV Infusion

Revision date: 28-Aug-2009 Version: 2.2

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Metronidazole

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 3800 mg/kg

Mouse Intraperitoneal LD 50 870 mg/kg

SODIUM CHLORIDE

Rat Inhalation LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Metronidazole

Eye Irritation Rabbit No effect

SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Citric Acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Metronidazole

2 Year(s) Mouse Oral 600 mg/kg LOAEL 80 Week(s) Rat Oral 30 mg/kg LOAEL

34 Day(s) Rat Oral = 34 g/kg LOAEL Kidney Ureter Bladder

4 Month(s) Dog Oral 75 mg/kg LOAEL

1 Year(s) Non-human Primate Oral 150 mg/kg LOAEL

Repeated Dose Toxicity Comments: Metronidazole produced tumors in mice and rats.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Metronidazole

Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Fertility

Page 5 of 7

Material Name: Metronidazole 500 mg IV Infusion

Revision date: 28-Aug-2009 Version: 2.2

11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility Rabbit Oral 200 mg/kg NOAEL Fertility, Developmental toxicity, Fetotoxicity

Embryo / Fetal Development Mouse Intraperitoneal 9 mg/kg LOAEL Fetotoxicity

Embryo / Fetal Development Rat Oral 200 mg/kg NOEL Not Teratogenic

Embryo / Fetal Development Mouse Intraperitoneal 40 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Metronidazole

In Vitro Bacterial Mutagenicity (Ames) Salmonella Positive
In Vitro Sister Chromatid Exchange Hamster Negative
In Vivo Unscheduled DNA Synthesis Rabbit Negative

In Vivo Micronucleus Rat Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Metronidazole

Not specified Rat Oral Tumors

Not specified Mouse Oral Tumors

Carcinogen Status: See below

Metronidazole

IARC: Group 2B
NTP: Listed
OSHA: Present

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Metronidazole

Mysid Shrimp OECD LC-50 96 Hours >180 mg/L

Sheepshead Minnow OECD LC-50 96 Hours >1060 mg/L

Aquatic Toxicity Comments:

A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 6 of 7

Material Name: Metronidazole 500 mg IV Infusion

Revision date: 28-Aug-2009 Version: 2.2

14. TRANSPORT INFORMATION

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Metronidazole

California Proposition 65Listed; CancerAustralia (AICS):Listed

Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 207-136-1

Sodium Phosphate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

231-558-5

SODIUM CHLORIDE

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

231-598-3

Citric Acid

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

201-069-1

Water for Injection

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Material Name: Metronidazole 500 mg IV Infusion Page 7 of 7

Revision date: 28-Aug-2009 Version: 2.2

15. REGULATORY INFORMATION

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R40 - Limited evidence of a carcinogenic effect R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 -

Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet